

## CURRICULUM VITAE

Jeanette Marie Tetrault, MD, FACP, FASAM

Version Date: 1/10/2024

### Contact Information:

Address 367 Cedar Street  
Ste Suite 305  
New Haven, CT 06510  
Phone: 1 (203) 785-5208  
Email: jeanette.tetrault@yale.edu

School: Yale School of Medicine

### Education:

09/1993 - 05/1997 BA, Boston University, Biology, Boston, MA  
07/1997 - 05/2001 MD, Boston University School of Medicine, Boston, MA

### Career/Academic Appointments:

01/2001 - 01/2004 Medical Intern and Resident, Internal Medicine-Primary Care, Yale School of Medicine, New Haven, CT  
01/2004 - 01/2005 Chief Resident, Internal Medicine-Primary Care, Yale School of Medicine, New Haven, CT  
07/2004 - 06/2005 Instructor, Internal Medicine, Yale School of Medicine, New Haven, CT  
01/2005 - 01/2007 Ambulatory Care Fellow, Clinical Epidemiology Research Fellow, West Haven VA Hospital, West Haven, CT  
07/2005 - 06/2007 Postdoctoral Fellow, General Medicine, Yale School of Medicine, New Haven, CT  
07/2007 - 06/2008 Instructor, General Medicine, Yale School of Medicine, New Haven, CT  
07/2008 - 06/2015 Assistant Professor, General Medicine, Yale School of Medicine, New Haven, CT  
07/2015 - 06/2021 Associate Professor on Term, General Medicine, Yale School of Medicine, New Haven, CT  
07/2020 - Present Professor, General Medicine, Yale School of Medicine, New Haven, CT  
03/2021 - 06/2025 Professor, Chronic Disease Epidemiology, Yale School of Medicine, New Haven, CT

### Administrative Positions:

2014 - Present Program Director, Addiction Medicine Fellowship, Internal Medicine, Yale School of Medicine, New Haven, CT

2014 - Present	Co-Director, Addiction Recovery Clinic: Chronic Disease Management/Residency Education Clinic, St. Raphael's Campus, Internal Medicine, Yale New Haven Hosp, New Haven, CT
2019 - Present	Associate Director for Education and Training, Program in Addiction Medicine, Internal Medicine, Yale School of Medicine, New Haven, CT
2019 - Present	Academic Advisor, Office of Student Affairs, Yale School of Medicine, New Haven, CT
2021 - Present	Professor, Chronic Disease Epidemiology, Yale School of Public Health, New Haven, CT
2021 - Present	Vice-chief for Education, General Internal Medicine, Yale School of Medicine, New Haven, CT

#### Board Certification:

2004 - 2015	AB of Internal Medicine, Internal Medicine
2015 - 2023	AB of Internal Medicine, Internal Medicine, recertification
2018 - 2028	AB of Preventive Medicine, Addiction Medicine

#### Professional Honors & Recognition:

##### International/National/Regional

1997	Phi Beta Kapa, Boston University
2001	Job E. Fuchs Scholarship Award for Humanism in Medicine, Boston University School of Medicine
2006	Best Research Abstract in Women's Medicine, Society of General Internal Medicine Annual Meeting, Los Angeles, CA
2010	Selected as a Hamolsky Award Finalist for Outstanding Junior Investigator Oral Abstract Presentation, 33rd Annual Society of General Internal Medicine Meeting, Minneapolis, MN
2010	Certified as an HIV Specialist, American Academy of HIV Medicine
2010	Selected as Invited Fellow, American College of Physicians
2011	Selected as Co-chair Alcohol, Tobacco, and Other Drug Use Interest Group, Society of General Internal Medicine
2011	Loan Repayment Award Recipient, National Institute of Health
2013	Clinician Educator of the Year, Society of General Internal Medicine-New England Regional Award for Excellence
2014	Elected President, Society of General Internal Medicine, New England Region
2017	Recognized Macy Foundation Faculty Scholar, Macy Foundation
2017	Elected as Milestones Committee Chair, The Addiction Medicine Foundation
2018	Awarded W. Anderson Spickard Excellence in Mentorship Award, Association for Multidisciplinary Education and Research in Substance Use and Addiction
2019	Elected as President, American College of Academic Addiction Medicine
2021	Annual Training Directors Award, American Society of Addiction Medicine
2023	John P. McGovern Award for Excellence in Medical Education, Association for Multidisciplinary Education and Research in Substance Use and Addiction

**Yale University/Yale School of Medicine/Hospital System**

2004 Selected as Chief Medical Resident, Yale University Primary Care Internal  
Medicine Residency Program

2011 George Thornton Community Teacher of the Year Award, Yale School of Medicine  
Primary Care Internal Medicine Residency Program

**Grants/Clinical Trials History:**

**Current Grants**

Agency: HRSA  
I.D.#: T0BHP3107  
Title: Primary Care Training and Enhancement  
Role: Principal Investigator  
Percent effort: 20%  
Total costs: \$1,976,565.00  
Project period: 07/01/2019 - 06/30/2024

Agency: HRSA  
I.D.#: 1 T25HP37631  
Title: Yale Addiction Fellowship Expansion Program  
Role: Principal Investigator  
Percent effort: 10%  
Total costs: \$2,660,078.00  
Project period: 06/03/2020 - 06/30/2025

Agency: Shatterproof  
I.D.#: AWD0008883  
Title: Shatterproof Reducing Healthcare Providers' Addiction Stigma to Better Serve  
Socially Vulnerable Communities  
P.I.: Tetrault  
Role: Co-Investigator; Site Principal Investigator  
Percent effort: 10%  
Total costs: \$200,000.00  
Project period: 10/01/2022 - 09/30/2025

**Past Grants**

Agency: SAMHSA  
I.D.#: 1U79TI025362-01  
Title: Yale-SBIRT Medical Health Professional Training Program  
P.I.: Gail D'Onofrio  
Role: Co-Investigator  
Percent effort: 10%

Total costs: \$943,785.00  
Project period: 09/01/2014 - 08/31/2017

Agency: NIDA  
I.D.#: 1R01DA035616-01  
Title: Using the VACS Index to track health outcomes associated with changes in drug use  
P.I.: Fiellin, David and Amy Justice  
Role: Co-Investigator  
Percent effort: 7%  
Total costs: \$1,190,178.00  
Project period: 04/01/2013 - 02/29/2016

Agency: NHLBI  
I.D.#: 1R18HL108788-01A1  
Title: Implementation of HIT-Enhanced Tobacco Treatment for Hospitalized Smokers  
Role: Co-Investigator  
Percent effort: 7%  
Total costs: \$731,166.00  
Project period: 08/06/2012 - 07/31/2015

Agency: HRSA  
I.D.#: D5FHP20670  
Title: Training in Primary Care Medicine and Dentistry: Residency Training in Primary Care  
P.I.: Nawaz, Haq  
Role: Consultant  
Percent effort: N/A  
Total costs: \$111,338.00  
Project period: 11/01/2010 - 08/31/2015

Agency: NIDA  
I.D.#: 5R01DA020576  
Title: Buprenorphine Maintenance vs. Detoxification in Prescription Opioid Dependence  
P.I.: David Fiellin  
Role: Co-Investigator  
Percent effort: 5%  
Total costs: \$2,865,450.00  
Project period: 07/05/2007 - 04/30/2013

Agency: SAMHSA  
I.D.#: 1U79TI020253-01

Title:	The SBIRT Training in Yale Residency Programs: Implementation and Dissemination to implement and disseminate SBIRT curriculum for alcohol/drugs into targeted Yale residencies and beyond
P.I.:	Gail D'Onofrio
Role:	Co-Investigator
Percent effort:	15%
Total costs:	\$1,869,686.00
Project period:	09/30/2008 - 09/13/2013
Agency:	HRSA
I.D.#:	D5HHP18960
Title:	Training in Primary Care Medicine and Dentistry: Residency Training in Primary Care
P.I.:	Nawaz, Haq
Role:	Consultant
Percent effort:	N/A
Total costs:	\$88,663.00
Project period:	07/01/2010 - 06/30/2013
Agency:	HRSA
I.D.#:	1H4AHA22762-01-00
Title:	Capacity Building for the Yale Graduate Medical Education HIV Training Program
P.I.:	Barakat, Lydia
Role:	Co-Investigator
Percent effort:	5%
Total costs:	\$450,000.00
Project period:	09/01/2011 - 09/30/2014
Agency:	HRSA
I.D.#:	3H80CS00741
Title:	Substance Abuse Service Expansion for Federally Qualified Health Centers
P.I.:	Lagarde, Suzanne
Role:	Co-Investigator
Percent effort:	20%
Total costs:	\$48,265.00
Project period:	04/01/2016 - 03/31/2017
Agency:	HRSA
I.D.#:	D33HP26994
Title:	Preventive Medicine Residencies
P.I.:	Nawaz, Haq
Role:	Consultant
Percent effort:	N/A

Total costs: \$500,000.00  
Project period: 07/01/2014 - 06/30/2018

Agency: HRSA  
I.D.#: TOBHP28572  
Title: Primary Care Training and Enhancement  
P.I.: Nawaz, Haq  
Role: Consultant  
Percent effort: N/A  
Total costs: \$349,998.00  
Project period: 07/01/2015 - 06/30/2020

Agency: SAMHSA  
I.D.#: H79TI081358  
Title: Minority Fellowship Program  
P.I.: Cathryn Cates-Wessel  
Role: Co-Investigator  
Percent effort: 5%  
Total costs: \$4,998,265.00  
Project period: 09/30/2018 - 09/29/2023

Agency: SAMHSA  
I.D.#: H79TI081659  
Title: Yale MAT Training Program  
P.I.: Gail D'Onofrio  
Role: Co-Investigator  
Percent effort: 5%  
Total costs: \$449,727.00  
Project period: 09/30/2018 - 09/29/2021

Agency: Macy Foundation  
I.D.#: AWD0000485  
Title: Macy Faculty Scholar Award  
Role: Principal Investigator  
Percent effort: 50%  
Total costs: \$278,993.00  
Project period: 09/01/2017 - 08/31/2019

Agency: Substance Abuse and Mental Health Services Administration  
I.D.#: 1 H79 FG0000-23  
Title: Expansion of Interprofessional Practitioner Substance Use Disorder Education  
P.I.: Cates-Wessel, K  
Role: Collaborator  
Percent effort: N/A

Total costs: \$201,299.00  
Project period: 09/30/2019 - 09/29/2021

Agency: US Department of State  
I.D.#: SJO10021GR3024  
Title: Yale – The University of Jordan Joint Training Program in Addiction Medicine  
P.I.: Jeanette M. Tetrault  
Role: Principle Investigator  
Percent effort: 5%  
Total costs: \$158,466.00  
Project period: 07/15/2021 - 06/14/2023

### Invited Speaking Engagements, Presentations & Workshops Not Affiliated With Yale: International/National

1. "Medical co-morbidities of substance abuse, Clinical Management, Special Populations". American Psychiatric Association; Faculty Instructor: Buprenorphine for the treatment of opioid dependence physician training course, Medical co-morbidities of substance abuse, Clinical Management, Special Populations, Orlando, FL, July 2007. (Oral Presentation)
2. "Medical co-morbidities of substance abuse, Clinical Management, Special Populations". American Psychiatric Association, Buprenorphine for the treatment of opioid dependence physician training course, Medical co-morbidities of substance abuse, Clinical Management, Special Populations, Orlando, FL, July 2007. (Oral Presentation)
3. "Buprenorphine and Medical Co-Morbidities". American Psychiatric Association and The Physicians Clinical Support System-Buprenorphine, Webinar, Buprenorphine and Medical Co-Morbidities, Washington, DC, July 2010. (Other)
4. "Marijuana: What every physician needs to know". Chief Resident Immersion Training in Addiction Medicine Course, Marijuana: What every physician needs to know, Harwich, MA, April 2012. (Other)
5. "For every ill there may be a pill: Treating substance use disorders with medication". American Society of Addiction Medicine, Fundamentals of Addiction Medicine, For every ill there may be a pill: Treating substance use disorders with medication, Orlando, FL, April 2013. (Oral Presentation)
6. "Marijuana: Clearing the Smoke on Clinical and Policy Issues". Chief Resident Immersion Training in Addiction Medicine Course, Marijuana: Clearing the Smoke on Clinical and Policy Issues, Harwich, MA, April 2013. (Other)
7. "Substance Use and Abuse Multiple Small Feedings of the Mind". American College of Physicians Annual Meeting, Substance Use and Abuse Multiple Small Feedings of the Mind, Boston, MA, April 2014. (Other)
8. "Marijuana: Clearing the Smoke on Clinical and Policy Issues". Chief Resident Immersion Training in Addiction Medicine Course, Marijuana: Clearing the Smoke on Clinical and Policy Issues, Harwich, MA, January 2015. (Other)
9. "Small Group Teaching". New England Region Society of General Internal Medicine Teaching Skills Retreat, Small Group Teaching, Boston, MA, February 2015. (Oral Presentation)

10. "Marijuana clinical and policy issues". Physicians Clinical Support System for Opioid Therapies, Small Group Discussion Webinar, Marijuana clinical and policy issues, Providence, RI, March 2015. (Other)
11. "Medication Assisted Treatment of Hepatitis C, HIV and Opioid Use Disorder". Physicians Clinical Support System for Medication Assisted Treatment of Hepatitis C, HIV and Opioid Use Disorder Webinar., Medication Assisted Treatment of Hepatitis C, HIV and Opioid Use Disorder, Providence, RI, March 2015. (Other)
12. "Involvement of nursing and other professions in alcohol screening and brief intervention: A critical review". International Network on Brief Interventions for Alcohol and Other Drugs (INEBRIA) Annual Conference; Precourse plenary presentation, Involvement of nursing and other professions in alcohol screening and brief intervention: A critical review, Atlanta, GA, September 2015. (Other)
13. "Adverse effects of marijuana use in adults". A public forum on The Marijuana Regulation, Control, and Taxation Act, Adverse effects of marijuana use in adults, Providence, RI, November 2015. (Oral Presentation)
14. "Training in Addiction Medicine: Possibilities in Vietnam". Hanoi Medical University, Visiting Professor, Training in Addiction Medicine: Possibilities in Vietnam, Hanoi, Hanoi, Vietnam, February 2016. (Oral Presentation)
15. "Training in Addiction Medicine: The U.S. Experience". Hanoi Medical University, Visiting Professor, Training in Addiction Medicine: The U.S. Experience, Hanoi, Hanoi, Vietnam, February 2016. (Oral Presentation)
16. "Small Group Teaching". New England Region Society of General Internal Medicine Teaching Skills Retreat, Small Group Teaching, Boston, MA, March 2016. (Oral Presentation)
17. "Marijuana: Clearing the Smoke on Clinical and Policy Issues". Chief Resident Immersion Training in Addiction Medicine Course, Marijuana: Clearing the Smoke on Clinical and Policy Issues, Harwich, MA, April 2016. (Oral Presentation)
18. "Office management of Opioid Use Disorder". Fundamentals of Addiction Medicine, Recognition Program, Tele ECHO clinics webinar., Office management of Opioid Use Disorder, Rockville, MD, August 2016. (Other)
19. "Cannabinoids". Fundamentals of Addiction Medicine, Recognition Program, Tele ECHO clinics webinar., Cannabinoids, Rockville, MD, October 2016. (Other)
20. "Building the Pipeline for Addiction Medicine Fellowship Applicants". Addiction Medicine Fellowship Directors Association Annual Meeting. Panel discussion moderator, Building the Pipeline for Addiction Medicine Fellowship Applicants, New Orleans, LA, April 2017. (Other)
21. "Screening and Treatment for Hepatitis C among People Who Use Drugs". American Society of Addiction Medicine Annual Meeting. Workshop facilitator, Screening and Treatment for Hepatitis C among People Who Use Drugs., New Orleans, LA, April 2017. (Other)
22. "Opening Pandora's Box: Introduction to Screening, Brief Intervention and Referral to Treatment". American Society of Addiction Medicine, Fundamentals of Addiction Medicine, Opening Pandora's Box: Introduction to Screening, Brief Intervention and Referral to Treatment, New Orleans, LA, April 2017. (Oral Presentation)
23. "Marijuana: Clearing the Smoke on Clinical and Policy Issues". Chief Resident Immersion Training in Addiction Medicine Course, Core faculty and lecturer, Marijuana: Clearing the Smoke on Clinical and Policy Issues, Beverly, MA, April 2017. (Oral Presentation)



24. "Care in the Face of the Opioid Epidemic: How Teaching Hospitals are Reaching Underserved Communities". Association of American Medical Colleges, Congressional Briefing on the Opioid Crisis, one of three panelists, Care in the Face of the Opioid Epidemic: How Teaching Hospitals are Reaching Underserved Communities, Washington, DC, October 2017. (Other)
25. "Marijuana: Clearing the Smoke on Clinical and Policy Issues". Chief Resident Immersion Training in Addiction Medicine Course, Core faculty and lecturer, Marijuana: Clearing the Smoke on Clinical and Policy Issues, Beverly, MA, April 2018. (Oral Presentation)
26. "Opportunities and Barriers: Education and training to expand treatment". National Academy of Science Engineering and Medicine. Workshop for the Committee on Medication Assisted Treatment for Opioid Use Disorder, Opportunities and Barriers: Education and training to expand treatment.", Washington, DC, October 2018. (Other)
27. "Breaking Badness: The HIV Provider's Role in Caring for Patients with Substance Use". University of California San Francisco. HIV Medicine Grand Rounds, Breaking badness: The HIV provider's role in caring for patients with substance use, San Francisco, CA, November 2018. (Oral Presentation)
28. "Achieving HCV Elimination in the US: Next steps". Clinical Care Options. Panelist, "Achieving HCV Elimination in the US: Next steps.", Orlando, FL, January 2019. (Other)
29. "Keys to setting up a successful Addiction Medicine Fellowship Program". American Society of Addiction Medicine. Workshop facilitator, "Keys to setting up a successful Addiction Medicine Fellowship Program.", Orlando, FL, April 2019. (Oral Presentation)
30. "The Role of the Addiction Medicine Specialist in the ED". Building the Addiction Medicine Workforce: Giving Americans Access to the Care They Need. Office of National Drug Control and Policy, White House Conference, Panel speaker, "The Role of the Addiction Medicine Specialist in the ED", Washington, DC, June 2019. (Oral Presentation)
31. "Building the Addiction Medicine Workforce: All Hands on Deck". American Society of Addiction Medicine 51st Annual Meeting. Symposia panelist., Building the Addiction Medicine Workforce: All Hands on Deck, Online annual meeting, April 2020. (Lecture)
32. "Should You Recommend Cannabinoids for This Patient With Painful Neuropathy?: Grand Rounds Discussion From Beth Israel Deaconess Medical Center.". Harvard Medical School-Beth Israel Deaconess Hospital, Should You Recommend Cannabinoids for This Patient With Painful Neuropathy?: Grand Rounds Discussion From Beth Israel Deaconess Medical Center., Grand Rounds Conference held virtually due to COVID19 pandemic, October 2020. (Lecture)
33. "Cannabis: Clearing the Smoke on Clinical and Policy Issues". Chief Resident, Fellow and Junior Faculty Immersion Training Conference, Boston University School of Medicine, Cannabis: Clearing the Smoke on Clinical and Policy Issues, Four day intensive training program on teaching and research on Addiction Medicine. Conference held virtually due to COVID-19 pandemic., October 2020. (Oral Presentation)
34. "Introduction to Motivational Interviewing: Helping People Change". Chief Resident, Fellow, and Junior Faculty Immersion Training Conference, Boston University School of Medicine, Introduction to Motivational Interviewing: Helping People Change, Four day intensive training program on teaching and research on Addiction Medicine. Conference held virtually due to COVID-19 pandemic., October 2020. (Oral Presentation)
35. "Health Professional Education and Training Workgroup Panelist". National Academy of Medicine, Washington DC, Health Professional Education and Training Workgroup Panelist, Served as panelist

- addressing the The Action Collaborative on Countering the U.S. Opioid Epidemic. Conference held virtually due to COVID-19 pandemic., November 2020. (Other)
36. "Introduction to Motivational Interviewing: Helping People Change". Chief Resident, Fellow, and Junior Faculty Immersion Training Conference, Boston University School of Medicine, Four day intensive training program on teaching and research on Addiction Medicine., "Introduction to Motivational Interviewing: Helping People Change", Conference held virtually due to COVID-19 pandemic., January 2021. (Other)
  37. "Cannabis: Clearing the smoke on clinical and policy issues". Chief Resident, Fellow, and Junior Faculty Immersion Training Conference, Boston University School of Medicine, Four day intensive training program on teaching and research on Addiction Medicine., Cannabis: Clearing the smoke on clinical and policy issues, Conference held virtually due to COVID-19 pandemic., January 2021. (Other)
  38. "Medical Co-morbidities in Patients with Substance Use Disorder". American College of Academic Addiction Medicine, Medical Co-morbidities in Patients with Substance Use Disorder, Lecture delivered as part of weekly national didactic curriculum, January 2021. (Lecture)
  39. "Addiction Medicine Milestones and GME Stakeholders Confronting the Opioid Epidemic". Accreditation Council of Graduate Medical Education, Chicago IL, Addiction Medicine Milestones and GME Stakeholders Confronting the Opioid Epidemic, Served as session moderator and panelist. Conference held virtually due to COVID-19 pandemic., April 2021. (Other)
  40. "Cannabis". Boston University, Chief Resident Immersion Training Conference, Beverly, MA, April 2022. (Lecture)
  41. "Motivational Interviewing". Boston University, Chief Resident Immersion Training Conference, Beverly, MA, April 2022. (Lecture)
  42. "Co-Occurring Medical Disorders among Individuals who Inject Drugs". American College of Academic Addiction Medicine (ACAAM), ACAAM National Didactic Series, Virtual presentation to all ACAAM Addiction Medicine Fellowships, November 2022. (Lecture)
  43. "Featured Plenary: Preparing Learners to Care for Substance Use Disorder". Accreditation Council of Graduate Medical Education (ACGME), Accreditation Council of Graduate Medical Education (ACGME) Annual Conference, Nashville, TN, February 2023. (Address)

## Regional

1. "Prescription Drug Abuse". Nurse Practitioner Association Annual Meeting, Prescription Drug Abuse, Verona, NY, October 2008. (Oral Presentation)
2. "Screening Brief Intervention and Referral to Treatment (SBIRT) Program". Medical Grand Rounds, Albany Medical Center, Screening Brief Intervention and Referral to Treatment (SBIRT) Program, Albany, NY, June 2010. (Oral Presentation)
3. "Screening, Brief Intervention and Referral to Treatment in the Emergency Department". Medical Grand Rounds, Albany Medical Center, Screening, Brief Intervention and Referral to Treatment in the Emergency Department, Albany, NY, June 2011. (Oral Presentation)
4. "Introduction to Screening, Brief Intervention, and Referral to Treatment". Albany Medical Center, Introduction to Screening, Brief Intervention, and Referral to Treatment., Albany, NY, June 2011. (Oral Presentation)

5. "Outpatient management of opioid use disorder". American College of Physicians, Connecticut State Chapter, Outpatient management of opioid use disorder, Southington, CT, October 2015. (Oral Presentation)
6. "Small Group Teaching". New England Region Society of General Internal Medicine Teaching Skills Retreat, Small Group Teaching, New Haven, CT, March 2016. (Oral Presentation)
7. "Why Are So Many Suboxone Patients Buying the Drug on the Street?". National Public Radio, Invited Speaker, <http://wnpr.org/post/why-are-so-many-suboxone-patients-buying-drug-street#stream/0>, Why Are So Many Suboxone Patients Buying the Drug on the Street?, New Haven, CT, September 2016. (Oral Presentation)
8. "Addicted babies and dirty addicts: Can we get in the habit of cleaning up our language?". Connecticut Opioid Response Initiative: Helping the media explain the opioid crisis and addiction to the public., Addicted babies and dirty addicts: Can we get in the habit of cleaning up our language?, New Haven, CT, June 2017. (Oral Presentation)
9. "Treatment of opioid use disorder in patients with chronic pain". Silver Hill Hospital Symposium on Opioid Epidemic, Treatment of opioid use disorder in patients with chronic pain, New Canaan, CT, October 2017. (Oral Presentation)
10. "Bridging the gap: Development and implementation of an inter professional, longitudinal clinical curriculum in substance use and addiction". Macy Foundation. Plenary Panel Speaker for 2017 Scholar Cohort Project Proposals, Bridging the gap: Development and implementation of an inter professional, longitudinal clinical curriculum in substance use and addiction, New York, NY, June 2018. (Other)
11. "Approaches to substance use across the spectrum: from SBIRT to medication treatment". Approaches to substance use across the spectrum: from SBIRT to medication treatment, Approaches to substance use across the spectrum: from SBIRT to medication treatment, Hartford, CT, September 2018. (Oral Presentation)
12. "Medication Assisted Treatment Waiver Training. MAT Trainer". CT Department of Public Health Combined Scope of Pain, Medication Assisted Treatment Waiver Training. MAT Trainer, Hartford, CT, October 2018. (Other)
13. "Developing a policy agenda to ameliorate barriers and increase access to opioid agonist treatment workshop. Work group member". Drug Policy Alliance, Developing a policy agenda to ameliorate barriers and increase access to opioid agonist treatment workshop. Work group member, New York, NY, November 2018. (Other)
14. "Breaking Badness: The Internist's Role in Addiction Medicine". Greater Waterbury Research Day, Keynote Speaker, "Breaking Badness: The Internist's Role in Addiction Medicine, Waterbury, CT, June 2019. (Oral Presentation)
15. "Bridging the gap: Development and implementation of an inter professional, longitudinal clinical curriculum in substance use and addiction". Macy Foundation. Plenary Panel Speaker for 2017 Scholar Cohort Project Updates, "Bridging the gap: Development and implementation of an inter professional, longitudinal clinical curriculum in substance use and addiction", New York, NY, June 2019. (Other)
16. "Hepatitis C in Patients with Substance Use Disorders". University of Kentucky, Hepatitis C in Patients with Substance Use Disorders, Grand Rounds Department of Psychiatry, February 2022. (Lecture)

17. "Substance Use Disorder". Yale Program in Addiction Medicine, Pain, Opioids, and Worker Wellness Training, Virtual half day training, September 2022. (Lecture)

## Peer-Reviewed Presentations Given at Meetings Not Affiliated With Yale:

### International/National

1. Effects of marijuana on pulmonary function: a systematic review. Society of General Internal Medicine (SGIM), Annual Meeting, Poster Presentation, Effects of marijuana on pulmonary function: a systematic review, Los Angeles, CA, April 2006. (Poster Presentation)
2. Risk factors associated with abuse of prescription opioids in women: results of a national survey. Society of General Internal Medicine (SGIM), Annual Meeting, Poster Presentation, Risk factors associated with abuse of prescription opioids in women: results of a national survey, Los Angeles, CA, April 2006. (Poster Presentation)
3. Factors associated with the abuse of prescription opioids in women: Results of a national survey. College on Problems of Drug Dependence (CPDD), Annual Meeting, Oral Presentation, Factors associated with the abuse of prescription opioids in women: Results of a national survey, Scottsdale, AZ, June 2006. (Oral Presentation)
4. Support and training of chief residents in management skills and conflict resolution. Association of Program Directors in Internal Medicine (APDIM) Annual Meeting, Oral Presentation, Support and training of chief residents in management skills and conflict resolution, Philadelphia, PA, September 2006. (Oral Presentation)
5. Quality of reporting of multivariable methods in the general medical literature. Society of General Internal Medicine (SGIM) Meeting, Poster Presentation, Quality of reporting of multivariable methods in the general medical literature, Toronto, ON, Canada, May 2007. (Poster Presentation)
6. Substance use in patients with sexually transmitted diseases: Results from a national survey. Society of General Internal Medicine (SGIM) Meeting, Poster Presentation, Substance use in patients with sexually transmitted diseases: Results from a national survey, Pittsburgh, PA, April 2008. (Poster Presentation)
7. Substance use in patients with sexually transmitted diseases: Results from a national survey. College on Problems of Drug Dependence (CPDD) Annual Meeting, Poster Presentation, Substance use in patients with sexually transmitted diseases: Results from a national survey, San Juan, San Juan, Puerto Rico, June 2008. (Poster Presentation)
8. Designing and implementing a multi-specialty graduate medical education curriculum on screening, brief intervention, and referral to treatment (SBIRT). Society of General Internal Medicine (SGIM) Meeting, Poster Presentation, Designing and implementing a multi-specialty graduate medical education curriculum on screening, brief intervention, and referral to treatment (SBIRT), Minneapolis, MN, May 2009. (Poster Presentation)
9. Hepatic safety and antiretroviral effectiveness in HIV-infected patients receiving naltrexone. Society of General Internal Medicine (SGIM) Meeting, Oral Presentation, Hamolsky Award Finalist., Hepatic safety and antiretroviral effectiveness in HIV-infected patients receiving naltrexone, Minneapolis, MN, May 2009. (Oral Presentation)
10. HIV transmission risk behaviors and antiretroviral resistance among HIV-infected patients on opioid agonist treatment. College on Problems of Drug Dependence (CPDD), Oral Presentation, HIV

- transmission risk behaviors and antiretroviral resistance among HIV-infected patients on opioid agonist treatment, Scottsdale, AZ, June 2009. (Oral Presentation)
11. Hepatic safety and antiretroviral effectiveness in HIV-infected patients receiving naltrexone. College on Problems of Drug Dependence (CPDD), Oral Presentation, Hepatic safety and antiretroviral effectiveness in HIV-infected patients receiving naltrexone, Scottsdale, AZ, June 2009. (Oral Presentation)
  12. Developing and Implementing a Multispecialty Graduate Medical Education Curriculum on Screening, Brief Intervention, and Referral to Treatment (SBIRT). Association for Medical Education and Research in Substance Abuse, Oral Presentation, Developing and Implementing a Multispecialty Graduate medical Education Curriculum on Screening, Brief Intervention, and Referral to Treatment (SBIRT), Bethesda, MD, November 2009. (Oral Presentation)
  13. Addiction update for the generalist. Society of General Internal Medicine (SGIM) Meeting, Oral Presentation, Addiction update for the generalist, Minneapolis, MN, May 2010. (Oral Presentation)
  14. HIV transmission risk behaviors and antiretroviral resistance among HIV-infected patients on opioid agonist treatment. Society of General Internal Medicine (SGIM), Poster Presentation, HIV transmission risk behaviors and antiretroviral resistance among HIV-infected patients on opioid agonist treatment.", Minneapolis, MN, May 2010. (Poster Presentation)
  15. Skills, attitudes, and training experiences regarding chronic pain management among residents. Association for Medical Education and Research in Substance Abuse (AMERSA) National Conference, Oral Presentation, Skills, attitudes, and training experiences regarding chronic pain management among residents, Arlington, VA, November 2010. (Oral Presentation)
  16. Brief versus extended counseling for HIV clinic-based buprenorphine treatment of opioid dependence: Project BRIGTH. Society of General Internal Medicine (SGIM) Annual Meeting, Oral Presentation, Society of General Internal Medicine Annual Meeting, Phoenix, AZ, May 2011. (Oral Presentation)
  17. Knowledge, skills and attitudes regarding identification and management of substance use among residents. Association for Medical Education and Research in Substance Abuse (AMERSA) National Conference, Poster Presentation, Knowledge, skills and attitudes regarding identification and management of substance use among residents, Arlington, VA, November 2011. (Poster Presentation)
  18. Use and safety of buprenorphine in HIV-infected and uninfected opioid dependent patients. Society of General Internal Medicine (SGIM) Annual Meeting, Poster Presentation, Use and safety of buprenorphine in HIV-infected and uninfected opioid dependent patients, Denver, CO, April 2013. (Poster Presentation)
  19. Update in Addiction Medicine for the Generalist. Society of General Internal Medicine (SGIM) Annual Meeting, Oral Presentation, Update in Addiction Medicine for the Generalist, Phoenix, AZ, April 2013. (Oral Presentation)
  20. Actual causes of death among patients enrolled in a methadone maintenance program. American Association for the Treatment of Opioid Dependence (AATOD) Meeting, Poster Presentation, Actual causes of death among patients enrolled in a methadone maintenance program, Philadelphia, PA, November 2013. (Poster Presentation)
  21. Enhanced uptake of Hepatitis C Treatment in an Opioid Treatment Program. American Society of Addiction Medicine (ASAM) Annual Meeting. Poster Presentation, Senior Author, Enhanced uptake

- of Hepatitis C Treatment in an Opioid Treatment Program, Austin, TX, April 2015. (Poster Presentation)
22. The Addiction Recovery Clinic: A novel primary-care based approach to teaching Addiction Medicine. Annual Meeting, Association for Medical Education and Research in Substance Abuse (AMERSA), Oral Presentation, Senior Author, The Addiction Recovery Clinic: A novel primary-care based approach to teaching Addiction Medicine, Washington, DC, November 2015. (Oral Presentation)
  23. Enhanced uptake of Hepatitis C Treatment in an Opioid Treatment Program. Association for Medical Education and Research and Substance Abuse (AMERSA) Annual Meeting, Oral Presentation, Senior author, Enhanced uptake of Hepatitis C Treatment in an Opioid Treatment Program, Washington, DC, November 2015. (Oral Presentation)
  24. Outcomes of a multispecialty graduate medical education curriculum on Screening, Brief Intervention, and Referral to Treatment for alcohol and other drug use. Society of General Internal Medicine (SGIM) Annual Meeting, Poster Presentation, Outcomes of a multispecialty graduate medical education curriculum on Screening, Brief Intervention, and Referral to Treatment for alcohol and other drug use, Hollywood, FL, April 2016. (Poster Presentation)
  25. Outcomes of a multispecialty graduate medical education curriculum on Screening, Brief Intervention, and Referral to Treatment for alcohol and other drug use. Association for Medical Education and Research and Substance Abuse (AMERSA) Annual Meeting, Poster Presentation, Outcomes of a multispecialty graduate medical education curriculum on Screening, Brief Intervention, and Referral to Treatment for alcohol and other drug use., Washington, DC, November 2016. (Poster Presentation)
  26. Substance use disorders in hospitalized patients with cirrhosis. American Society of Addiction Medicine Annual Meeting, Poster Presentation, (Senior Author, Lead Author: Haque, L) Lead author was awarded the New Investigator of the Year Award for work on this project., Substance use disorders in hospitalized patients with cirrhosis, New Orleans, LA, April 2017. (Poster Presentation)
  27. Development of the Yale Addiction Medicine Collaborative: An Inter-professional health student addiction medicine interest group. Association for Medical Education and Research and Substance Abuse (AMERSA) Annual Meeting, Poster Presentation, (Senior Author, Lead Author: Bone C), Development of the Yale Addiction Medicine Collaborative: An Inter-professional health student addiction medicine interest group, Washington, DC, November 2017. (Poster Presentation)
  28. It takes a village: Implementation of substance use screening in school-based health centers. Association for Medical Education and Research and Substance Abuse (AMERSA) Annual Meeting, Oral Presentation, (Senior Author, Lead Author: Haque, L), It takes a village: Implementation of substance use screening in school based health centers, Washington, DC, November 2017. (Oral Presentation)
  29. Harm reduction and opioid overdose training with naloxone for medical students in the clerkship years. Society for General Internal Medicine (SGIM) Annual Meeting, Poster Presentation, (Contributing Author, Lead Author: Oldfield, B.), Harm reduction and opioid overdose training with naloxone for medical students in the clerkship years, Denver, CO, May 2018. (Poster Presentation)
  30. Contraception Use and Risk of Unintended Pregnancy among Women Enrolling in Methadone Maintenance Treatment Program. College on Problems of Drug Dependence Annual Meeting, Poster Presentation, (Contributing Author, Lead Author: Bone, C.), Contraception Use and Risk of

Unintended Pregnancy among Women Enrolling in Methadone Maintenance Treatment Program, San Diego, CA, November 2018. (Poster Presentation)

31. Addiction Medicine and Psychiatry Co-visits in an Opioid Treatment Program. Association of Medical Education and Research in Substance use and Addiction (AMERSA), Annual Meeting, Poster Presentation (Contributing Author, Lead Author: Morford, K.), Addiction Medicine and Psychiatry Co-visits in an Opioid Treatment Program, San Francisco, CA, November 2018. (Poster Presentation)
32. Bridging the Gap: Development of an interprofessional workshop on taking a substance use history. Association for Multidisciplinary Education in Substance Use and Addiction (AMSERSA), Bridging the Gap: Development of an interprofessional workshop on taking a substance use history, Boston, MA, November 2019. (Oral Presentation)
33. Developing a Fellowship in the New Subspecialty of Addiction Medicine. Accreditation Council of Graduate Medical Education 2020 Annual Meeting. Symposium panelist, Developing a Fellowship in the New Subspecialty of Addiction Medicine, San Diego, CA, February 2020. (Oral Presentation)
34. What Residents and Fellows Need to Know About the Intersection of Pain and Addiction. Accreditation Council on Graduate Medical Education 2020 Annual Meeting. Workshop panelist., What Residents and Fellows Need to Know About the Intersection of Pain and Addiciton, San Diego, CA, February 2020. (Oral Presentation)
35. Interprofessional Addiction Education: Implementation Strategies for Online Training. Association for Multidisciplinary Education in Substance use and Addiction Annual Meeting, Interprofessional Addiction Education: Implementation Strategies for Online Training, Contributing author. Awarded the John Nelson Chappel Best Curricula, Quality Improvement and Program Abstract Award. Conference held virtually due to COVID-19 pandemic, November 2020. (Oral Presentation)
36. Emergency Department-Initiated Buprenorphine: An Opportunity for Generalists to Collaborate with ED's to Address the Opioid Crisis. Society of General Internal Medicine, Emergency Department-Initiated Buprenorphine: An Opportunity for Generalists to Collaborate with ED's to Address the Opioid Crisis, Conference held virtually due to the COVID19 pandemic, April 2021. (Oral Presentation)
37. Building the Addiction Medicine Workforce: All Hands on Deck. American Society of Addiction Medicine Annual Meeting, Building the Addiction Medicine Workforce: All Hands on Deck, Hollywood, FL, April 2022. (Oral Presentation)

## Regional

1. Hepatitis C Treatment in People with Opioid Dependence. American Academy of the Treatment of Opioid Dependence (AATOD) National Conference, Hepatitis C Treatment in People with Opioid Dependence, New York, NY, October 2009. (Oral Presentation)

## Professional Service:

### Peer Review Groups/Grant Study Sections

2021 - 2023                      Grant Reviewer, Accreditation Council for Continuing Medical Education, Independent Grant Review Committee, Served as grant reviewer for REMS Program Companies that make and market opioids to provide commercial

support to accredited continuing education for healthcare teams to promote safe prescribing and help combat the opioid crisis. Served in 2021 and 2022

## Advisory Boards

2020 - 2022 Scientific Advisor, Data Safety Monitoring Board, University of Washington, Serve as Independent Safety Monitor for NIDA Funded R34 (PI Judith Tsui, MD; University of Washington) pilot study of community pharmacy model for treating people who inject drugs who are infected with Hepatitis C

## Journal Services

### *Editorial boards*

2009 - 2020 Associate Editor, Alcohol, Other Drugs and Health: Current Evidence  
2012 Guest Editor, Addiction Treatment in Medical Settings, Journal of Substance Abuse Treatment, Guest Editor for Special Issue: Addiction Treatment in Medical Settings, Journal of Substance Abuse Treatment  
2012 Associate Editor, Medical Disorders and Complications of Addiction, for Principles of Addiction Medicine Textbook, 5th Edition  
2019 - Present Associate Editor, Principles of Addiction Medicine Textbook 7th Edition

### *Reviewer*

2005 - Present Reviewer, Reviewer for Addiction, Annals of Internal Medicine, Archives of General Psychiatry, BioMed Central: Medical Education, Clinical Medicine: Gastroenterology, Drug and Alcohol Dependence, Journal of Addiction Medicine, Journal of American Medical Association, Journal of General Internal Medicine, Journal of Managed Care, Journal of Substance Abuse Treatment, New England Journal of Medicine Substance Abuse  
2016 Reviewer, Medical Disorders and Complications of Addiction for Principles of Addiction Medicine Textbook, 6th Edition

## Professional Organizations

### *Addiction Medicine Fellowship Program Director's Association*

2016 - 2018 Member, Addiction Medicine Fellowship Program Director's Association  
2016 - 2018 Chair, Addiction Medicine Fellowship Program Director's Association

### *American College of Academic Addiction Medicine*

2017 - Present Director, American College of Academic Addiction Medicine, President-elect  
2019 - 2022 President-elect, American College of Academic Addiction Medicine, President-elect  
2019 - Present Chair, American College of Academic Addiction Medicine, Chair, ACGME Milestones subcommittee  
2022 - Present President, American College of Academic Addiction Medicine



*American College of Physicians*

2008 - Present	Member, American College of Physicians, Connecticut Health and Public Policy Committee, Member
2008 - 2013	Co-Chair, American College of Physicians, Connecticut Council of Young Physicians, Co-chair
2008 - 2013	Member, American College of Physicians, Connecticut Governor's Council, Member
2009 - 2014	Chairperson, American College of Physicians, Connecticut Chapter Council of Young Physicians

*American Society of Addiction Medicine*

2012 - Present	American Society of Addiction Medicine
2013 - Present	Vice Chair, American Society of Addiction Medicine, Course vice-chair, Fundamentals of Addiction Medicine Course
2013 - Present	Member, American Society of Addiction Medicine, Continuing Medical Education Committee member
2013	Chair, American Society of Addiction Medicine, Planning Committee Chair, Fundamentals of Addiction Medicine Course

*Association for Medical Education and Research in Substance Abuse*

2012 - Present	Member, Association for Medical Education and Research in Substance Abuse
----------------	---

*National Institute on Drug Abuse (NIDA) Clinical Decision Support Working Group*

2011	Expert Panel Member, National Institute on Drug Abuse (NIDA) Clinical Decision Support Working Group, Expert panel to establish Clinical Decision Support for implementation of Screening, Brief Intervention, and Referral to Treatment for Drug Use Disorders in Primary Care
------	---

*National Institute on Drug Abuse (NIDA) Clinical Trials Network Subthreshold Opioid Use Disorder Intervention Workgroup*

2018	Consultant, National Institute on Drug Abuse (NIDA) Clinical Trials Network Subthreshold Opioid Use Disorder Intervention Workgroup, Served as consultant to Clinical Trials Network panel for intervention development
------	---

*Providers Clinical Support System (PCSS)*

2010 - Present	Mentor, Providers Clinical Support System (PCSS), Providers Clinical Support System: Buprenorphine Mentor
2012 - Present	Member, Providers Clinical Support System (PCSS), Providers Clinical Support System-Opioids Member, Steering Committee

*Society of General Internal Medicine*

2004 - Present	Member, Society of General Internal Medicine, HIV/AIDS Task Force, Member
2004 - Present	Member, Society of General Internal Medicine, Pain Medicine Interest Group, Member
2004 - 2011	Member, Society of General Internal Medicine, Substance Abuse Interest Group, Member
2010 - Present	Reviewer, Society of General Internal Medicine, 33rd Annual Meeting, Mental Health and Substance Abuse Scientific Abstract Review Committee
2011 - 2018	Co-Chair, Society of General Internal Medicine, Alcohol, Tobacco and Other Drug Use Interest Group, Co-chair
2011 - 2014	Chairperson, Society of General Internal Medicine, Substance Abuse Interest Group
2012	Chair, Society of General Internal Medicine, 34th Annual Meeting Chair, Mental Health and Substance Abuse Workshop Review Committee
2013	Chair, Society of General Internal Medicine, 35th Annual Meeting, Chair, Mental Health and Substance Abuse Abstract Review Committee
2014	President, Society of General Internal Medicine, President elect, New England Region
2015	President, Society of General Internal Medicine, President, New England Region
2016	President, Society of General Internal Medicine, Past-president, New England Region

*Yale University/VA Connecticut Healthcare System Service*

2004 - Present	Committee Member, Yale University/VA Connecticut Healthcare System Service, Intern Selection Committee, Yale University Primary Care Internal Medicine Residency Program
2010 - 2016	Member, Yale University/VA Connecticut Healthcare System Service, Veterans Aging Cohort Study (VACS), Member, Liver Disease Core
2011 - 2013	Committee Member, Yale University/VA Connecticut Healthcare System Service, Intern Selection Committee, Yale University Traditional Residency Program
2013 - Present	Faculty Member, Yale University/VA Connecticut Healthcare System Service, Intern Selection Committee, Core Faculty Member HIV Training Track, Yale Primary Care Program
2016 - Present	Co-Chair, Yale University/VA Connecticut Healthcare System Service, Co-chair, Addiction Medicine curriculum committee for Yale School of Medicine
2016 - 2017	Committee Member, Yale University/VA Connecticut Healthcare System Service, Faculty Evaluation Committee, Member
2018 - Present	Member, Yale University/VA Connecticut Healthcare System Service, Member, The Committee on the Status of Women in Medicine

## Yale University / Hospital System

### *Medical School*

2009 - Present	Member, Intern Selection Committee, Interview new applicants to Yale Primary Care Internal Medicine Residency Program
2021 - Present	Member, YSM-YNHH Addiction Medicine/Addiction Psychiatry Services Steering Committee
2022 - Present	Member, Yale School of Medicine-Medical Student Subcommittee of LCME Self Study, Member of the medical student subcommittee of the YSM LCME Self Study Task Force

### *Hospital*

2022 - Present	Member, Yale New Haven Hospital-Ambulatory treatment of OUD pathway Committee, Serve as a member of the YNHH ambulatory treatment of OUD pathway committee
----------------	--

## Public Service / Media Presence

### *Media Presence*

2016 - Present	Participant, NPR, Invited guest to talk about treatment for opioid use disorder
2021 - Present	Participant, NPR, Invited guest on CT Public Radio to discuss alcohol use disorder in women
2022 - Present	Participant, Curbsiders Addiction Medicine Podcast, Invited speaker for podcast focusing on decreasing stigma in addiction medicine

## Bibliography:

### Peer-Reviewed Original Research

1. Donroe JH, **Tetrault JM**. Substance Use, Intoxication, and Withdrawal in the Critical Care Setting. *Critical Care Clinics* 2017, 33: 543-558. [PMID: 28601134](#), [DOI: 10.1016/j.ccc.2017.03.003](#).
2. Verplaetse TL, Weinberger AH, Oberleitner LM, Smith KM, Pittman BP, Shi JM, **Tetrault JM**, Lavery ME, Picciotto MR, McKee SA. Effect of doxazosin on stress reactivity and the ability to resist smoking. *Journal Of Psychopharmacology* 2017, 31: 830-840. [PMID: 28440105](#), [PMCID: PMC5823502](#), [DOI: 10.1177/0269881117699603](#).
3. Holt SR, Segar N, Cavallo DA, **Tetrault JM**. The Addiction Recovery Clinic. *Academic Medicine* 2017, 92: 680-683. [PMID: 28441678](#), [DOI: 10.1097/acm.0000000000001480](#).
4. Donroe JH, **Tetrault JM**. Recognizing and Caring for the Intoxicated Patient in an Outpatient Clinic. *Medical Clinics Of North America* 2017, 101: 573-586. [PMID: 28372714](#), [DOI: 10.1016/j.mcna.2016.12.012](#).
5. **Tetrault JM**, Petrakis IL. Partnering with Psychiatry to Close the Education Gap: An Approach to the Addiction Epidemic. *Journal Of General Internal Medicine* 2017, 32: 1387-1389. [PMID: 28766126](#), [PMCID: PMC5698217](#), [DOI: 10.1007/s11606-017-4140-9](#).
6. Donroe JH, Holt SR, O'Connor P, Sukumar N, **Tetrault JM**. Interpreting quantitative urine buprenorphine and norbuprenorphine levels in office-based clinical practice. *Drug And Alcohol Dependence* 2017, 180: 46-51. [PMID: 28866369](#), [DOI: 10.1016/j.drugalcdep.2017.07.040](#).

7. Deligianni M, **Tetrault J**. La réduction de la consommation de cannabis améliore les résultats fonctionnels au fil du temps. *Revue Médicale Suisse* 2018, 14: 2184. [PMID: 30484980](#), [DOI: 10.53738/revmed.2018.14.629.2184](#).
8. Holt SR, Donroe JH, Cavallo DA, **Tetrault JM**. Addressing discordant quantitative urine buprenorphine and norbuprenorphine levels: Case examples in opioid use disorder. *Drug And Alcohol Dependence* 2018, 186: 171-174. [PMID: 29579725](#), [DOI: 10.1016/j.drugalcdep.2017.12.040](#).
9. Donroe JH, **Tetrault JM**. Narrowing the treatment gap in managing opioid use disorder. *Canadian Medical Association Journal* 2018, 190: e236-e237. [PMID: 29507154](#), [PMCID: PMC5837871](#), [DOI: 10.1503/cmaj.180209](#).
10. Verplaetse TL, Weinberger AH, Ashare RL, Pittman BP, Shi JM, **Tetrault JM**, Lavery M, McKee SA. Pilot investigation of the effect of carvedilol on stress-precipitated smoking-lapse behavior. *Journal Of Psychopharmacology* 2018, 32: 1003-1009. [PMID: 29692206](#), [PMCID: PMC6258014](#), [DOI: 10.1177/0269881118767647](#).
11. Roberts W, Shi JM, **Tetrault JM**, McKee SA. Effects of Varenicline Alone and in Combination With Low-dose Naltrexone on Alcohol-primed Smoking in Heavy-drinking Tobacco Users. *Journal Of Addiction Medicine* 2018, 12: 227-233. [PMID: 29438157](#), [PMCID: PMC5970035](#), [DOI: 10.1097/adm.0000000000000392](#).
12. Edelman EJ, Oldfield BJ, **Tetrault JM**. Office-Based Addiction Treatment in Primary Care Approaches That Work. *Medical Clinics Of North America* 2018, 102: 635-652. [PMID: 29933820](#), [DOI: 10.1016/j.mcna.2018.02.007](#).
13. Barakat LA, Dunne DW, **Tetrault JM**, Soares S, Chia D, Ogbuagu OE, Moriarty JP, Huot SJ, Green ML. The Changing Face of HIV Care. *Academic Medicine* 2018, 93: 1673-1678. [PMID: 29901657](#), [DOI: 10.1097/acm.0000000000002317](#).
14. Oldfield BJ, Muñoz N, Boshnack N, Leavitt R, McGovern MP, Villanueva M, **Tetrault JM**, Edelman E. "No more falling through the cracks": A qualitative study to inform measurement of integration of care of HIV and opioid use disorder. *Journal Of Substance Abuse Treatment* 2018, 97: 28-40. [PMID: 30577897](#), [DOI: 10.1016/j.jsat.2018.11.007](#).
15. Weimer MB, Tetrault JM, Fiellin DA. Patients with opioid use disorder deserve trained providers. *Annals of Internal Medicine*. 2019.
16. Edelman EJ, **Tetrault JM**. Unhealthy Alcohol Use in Primary Care-The Elephant in the Examination Room. *JAMA Internal Medicine* 2019, 179: 9-10. [PMID: 30422276](#), [DOI: 10.1001/jamainternmed.2018.6125](#).
17. Bernstein SL, Weiss J, DeWitt M, **Tetrault JM**, Hsiao AL, Dziura J, Sussman S, Miller T, Carpenter K, O'Connor P, Toll B. A randomized trial of decision support for tobacco dependence treatment in an inpatient electronic medical record: clinical results. *Implementation Science* 2019, 14: 8. [PMID: 30670043](#), [PMCID: PMC6343239](#), [DOI: 10.1186/s13012-019-0856-8](#).
18. Andrews J, Jones C, **Tetrault J**, Coontz K. Advocacy Training for Residents. *Academic Medicine* 2019, 94: 204-207. [PMID: 30334843](#), [DOI: 10.1097/acm.0000000000002500](#).
19. Oldfield B, Muñoz N, McGovern M, Funaro M, Villanueva M, **Tetrault J**, Edelman E. Integration of care for HIV and opioid use disorder. *AIDS* 2019, Publish Ahead of Print: &na;. [PMID: 30882491](#), [PMCID: PMC6588508](#), [DOI: 10.1097/qad.0000000000002125](#).
20. de Laat B, Goldberg A, Shi J, **Tetrault JM**, Nabulsi N, Zheng MQ, Najafzadeh S, Gao H, Kapinos M, Ropchan J, O'Malley SS, Huang Y, Morris ED, Krishnan-Sarin S. The Kappa Opioid Receptor Is

- Associated With Naltrexone-Induced Reduction of Drinking and Craving. *Biological Psychiatry* 2019, 86: 864-871. [PMID: 31399255](#), [DOI: 10.1016/j.biopsych.2019.05.021](#).
21. Muzyk A, Smothers ZPW, Akrobetu D, Ruiz Veve J, MacEachern M, **Tetrault JM**, Grupen L. Substance Use Disorder Education in Medical Schools: A Scoping Review of the Literature. *Academic Medicine : Journal Of The Association Of American Medical Colleges* 2019 [PMID: 31348067](#), [DOI: 10.1097/ACM.0000000000002883](#).
22. Holt SR, Donroe JH, Cavallo DA, **Tetrault JM**. Corrigendum to “Addressing discordant quantitative urine buprenorphine and norbuprenorphine levels: Case examples in opioid use disorder” [*Drug Alcohol Depend*. 186 (2018) 171–174]. *Drug And Alcohol Dependence* 2019, 205: 107601. [PMID: 31593815](#), [DOI: 10.1016/j.drugalcdep.2019.107601](#).
23. Krishnan-Sarin S, O’Malley S, Franco N, Cavallo DA, **Tetrault JM**, Shi J, Gueorguieva R, Pittman B, Krystal JH. Influence of combined treatment with naltrexone and memantine on alcohol drinking behaviors: a phase II randomized crossover trial. *Neuropsychopharmacology* 2019, 45: 319-326. [PMID: 31590179](#), [PMCID: PMC6901445](#), [DOI: 10.1038/s41386-019-0536-z](#).
24. Edelman EJ, Moore BA, Calabrese SK, Berkenblit G, Cunningham CO, Ogbuagu O, Patel VV, Phillips KA, **Tetrault JM**, Shah M, Blackstock O. Preferences for implementation of HIV pre-exposure prophylaxis (PrEP): Results from a survey of primary care providers. *Preventive Medicine Reports* 2019, 17: 101012. [PMID: 31890474](#), [PMCID: PMC6926349](#), [DOI: 10.1016/j.pmedr.2019.101012](#).
25. Dunne D, Green M, **Tetrault J**, Barakat LA. Development of a Novel Competency-Based Evaluation System for HIV Primary Care Training: the HIV Entrustable Professional Activities. *Journal Of General Internal Medicine* 2019, 35: 331-335. [PMID: 31667752](#), [PMCID: PMC6957645](#), [DOI: 10.1007/s11606-019-04956-1](#).
26. Muzyk A, Smothers ZPW, Akrobetu D, Ruiz Veve J, MacEachern M, **Tetrault JM**, Gruppen L. Substance Use Disorder Education in Medical Schools: A Scoping Review. *Academic Medicine* 2019, 94: 1825-1834. [PMID: 31663960](#), [DOI: 10.1097/acm.0000000000002883](#).
27. Kansagara D, Becker WC, Ayers C, **Tetrault JM**. Priming primary care providers to engage in evidence-based discussions about cannabis with patients. *Addiction Science Clinical Practice* 2019, 14: 42. [PMID: 31787111](#), [PMCID: PMC6886188](#), [DOI: 10.1186/s13722-019-0171-3](#).
28. Roberts, A., Angoff, N. R., Brissette, D., Dupee, D., Fahs, D., Honan, L., Korbey, S., Roessler, E., Schwartz, M., Shabanova, V., Tetrault, J., Wu, B., Colson, E., Encandela, J. (2020). Burnout Among Beginning First-Year Students from Three Health Professional Training Programs. *Medical Science Educator*, 30(2), 879-883. <https://doi.org/10.1007/s40670-020-00969-2>
29. Oldfield BJ, **Tetrault JM**, Wilkins KM, Edelman EJ, Capurso NA. Opioid Overdose Prevention Education for Medical Students: Adopting Harm Reduction into Mandatory Clerkship Curricula. *Substance Abuse* 2020, 41: 29-34. [PMID: 31211657](#), [DOI: 10.1080/08897077.2019.1621241](#).
30. Muzyk A, Smothers ZPW, Andolsek KM, Bradner M, Bratberg JP, Clark SA, Collins K, Greskovic GA, Gruppen L, MacEachern M, Ramsey SE, Ruiz Veve J, **Tetrault JM**. Interprofessional Substance Use Disorder Education in Health Professions Education Programs: A Scoping Review. *Academic Medicine* 2020, 95: 470-480. [PMID: 31651435](#), [DOI: 10.1097/acm.0000000000003053](#).
31. Roberts A, Angoff NR, Brissette D, Dupee D, Fahs D, Honan L, Korbey S, Roessler E, Schwartz M, Shabanova V, **Tetrault J**, Wu B, Colson E, Encandela J. Burnout Among Beginning First-Year Students from Three Health Professional Training Programs. *Medical Science Educator* 2020, 30: 879-883. [PMID: 34457745](#), [PMCID: PMC8368543](#), [DOI: 10.1007/s40670-020-00969-2](#).

32. **Tetrault JM**, Holt SR, Cavallo DA, O'Connor PG, Gordon MA, Corvino JK, Nich C, Carroll KM. Computerized Cognitive Behavioral Therapy for Substance Use Disorders in a Specialized Primary Care Practice: A Randomized Feasibility Trial to Address the RT Component of SBIRT. *Journal Of Addiction Medicine* 2020, 14: e303-e309. [PMID: 32371660](#), [DOI: 10.1097/adm.0000000000000663](#).
33. Haque LY, Jakab S, Deng Y, Ciarleglio MM, **Tetrault JM**. Substance Use Disorders in Recently Hospitalized Patients With Cirrhosis. *Journal Of Addiction Medicine* 2020, 14: e337-e343. [PMID: 32530887](#), [PMCID: PMC9033633](#), [DOI: 10.1097/adm.0000000000000677](#).
34. Severe B, **Tetrault JM**, Madden L, Heimer R. Co-Located hepatitis C virus infection treatment within an opioid treatment program promotes opioid agonist treatment retention. *Drug And Alcohol Dependence* 2020, 213: 108116. [PMID: 32599493](#), [DOI: 10.1016/j.drugalcdep.2020.108116](#).
35. Muvvala SB, Schwartz ML, Petrakis I, O'Connor P, **Tetrault JM**. Stitching A Solution to the Addiction Epidemic: A Longitudinal Addiction Curricular Thread across Four Years of Medical Training. *Substance Abuse* 2020, 41: 475-479. [PMID: 31951809](#), [DOI: 10.1080/08897077.2019.1709606](#).
36. Bisio C, **Tetrault J**. Association entre l'usage de cannabis et les principales anomalies congénitales. *Revue Médicale Suisse* 2021, 17: 1334. [PMID: 34264039](#), [DOI: 10.53738/revmed.2021.17.745.1334](#).
37. Smetana GW, **Tetrault JM**, Hill KP, Burns RB. Should You Recommend Cannabinoids for This Patient With Painful Neuropathy? : Grand Rounds Discussion From Beth Israel Deaconess Medical Center. *Annals Of Internal Medicine* 2021, 174: 237-246. [PMID: 33556279](#), [DOI: 10.7326/m20-7945](#).
38. Oldfield BJ, **Tetrault JM**, Berland G. Addiction Screening—The A Star Is Born Movie Series and Destigmatization of Substance Use Disorders. *JAMA* 2021, 325: 915-917. [PMID: 33687448](#), [DOI: 10.1001/jama.2020.25256](#).
39. Thompson SL, Gianessi CA, O'Malley SS, Cavallo DA, Shi JM, **Tetrault JM**, DeMartini KS, Gueorguieva R, Pittman B, Krystal JH, Taylor JR, Krishnan-Sarin S. Saracatinib Fails to Reduce Alcohol-Seeking and Consumption in Mice and Human Participants. *Frontiers In Psychiatry* 2021, 12: 709559. [PMID: 34531767](#), [PMCID: PMC8438169](#), [DOI: 10.3389/fpsy.2021.709559](#).
40. Morford K, Falker C, **Tetrault J**. Training Medical Students, Residents, and Fellows in Opioid Use Disorder Treatment. 2021, 161-171. [DOI: 10.1007/978-3-030-80818-1\\_11](#).
41. Du CX, Shi J, **Tetrault JM**, Madden LM, Barry DT. Primary care and medication management characteristics among patients receiving office-based opioid treatment with buprenorphine. *Family Practice* 2021, 39: 234-240. [PMID: 34893825](#), [PMCID: PMC8947790](#), [DOI: 10.1093/fampra/cmab166](#).
42. Cohen SM, Weimer MB, Levander XA, Peckham AM, **Tetrault JM**, Morford KL. Low Dose Initiation of Buprenorphine: A Narrative Review and Practical Approach. *Journal Of Addiction Medicine* 2021, 16: 399-406. [PMID: 34954746](#), [DOI: 10.1097/adm.0000000000000945](#).
43. Shi J, Slocum B, **Tetrault J**, Yanagisawa K. Chapter 9 Addiction management in the outpatient setting. 2022, 169-187. [DOI: 10.1016/b978-0-323-79016-1.00008-8](#).
44. Viera A, Grau L, Fisher J, Farnum S, **Tetrault J**, Scott G, Heimer R. Development and pilot-testing of a hepatitis C reinfection prevention intervention for patients in treatment for hepatitis C infection. *Drug And Alcohol Dependence Reports* 2022, 3: 100038. [PMID: 36845980](#), [PMCID: PMC9948939](#), [DOI: 10.1016/j.dadr.2022.100038](#).
45. Haque LY, Butner JL, Shi JM, Henry S, Deng Y, Ciarleglio MM, Madden LM, **Tetrault JM**. Primary Care Associated With Follow Up Viral Load Testing in Patients Cured of Hepatitis C Infection With Direct Acting Antivirals at a Multidisciplinary Addiction Treatment Program: Insights From a Real-

- World Setting. *Journal Of Addiction Medicine* 2022, 16: 333-339. [PMID: 34483278](#), [PMCID: PMC9033626](#), [DOI: 10.1097/adm.0000000000000910](#).
46. Barcelona V, Wischik DL, Marshall A, **Tetrault JM**. Integration of medication for opioid use disorder training into graduate nursing education. *Nursing Forum* 2022, 57: 869-873. [PMID: 35616353](#), [DOI: 10.1111/nuf.12753](#).
  47. Morford KL, Batchelor HM, **Tetrault JM**. Grief at the Heart of the Opioid Overdose Crisis: Past Lessons and Present Implications. *Journal Of Addiction Medicine* 2022, 16: 613-615. [PMID: 35165230](#), [DOI: 10.1097/adm.0000000000000976](#).
  48. Morford K, **Tetrault J**, Zhou B, Li F, Gleeson B, Edelman E, Stein M, Barry D, Madden L. The impact of benzodiazepine exposure on treatment retention in an open-access methadone program: A retrospective cohort study. *Drug And Alcohol Dependence* 2022, 241: 109707. [PMID: 36423462](#), [PMCID: PMC9777057](#), [DOI: 10.1016/j.drugalcdep.2022.109707](#).
  49. Haque L, Fiellin D, Tate J, Esserman D, Bhattacharya D, Butt A, Crystal S, Edelman E, Gordon A, Lim J, **Tetrault J**, Williams E, Bryant K, Cartwright E, Rentsch C, Justice A, Re V, McGinnis K. Association Between Alcohol Use Disorder and Receipt of Direct-Acting Antiviral Hepatitis C Virus Treatment. *JAMA Network Open* 2022, 5: e2246604. [PMID: 36515952](#), [PMCID: PMC9856353](#), [DOI: 10.1001/jamanetworkopen.2022.46604](#).
  50. Brooks R, Wegener M, Freeman B, Fowles C, Madden L, **Tetrault J**, Nichols L, Altice F, Villanueva M. Improving HIV and HCV Testing in Substance Use Disorder Programs (SUDs) That Provide Medications for Opiate Use Disorder (MOUD): Role of Addressing Barriers and Implementing Universal and Site-Specific Approaches. *Health Promotion Practice* 2023, 24: 1018-1028. [PMID: 37439759](#), [DOI: 10.1177/15248399231169791](#).
  51. Huxley-Reicher Z, Puglisi L, **Tetrault J**, Weimer M, Stellini M, Bhandary-Alexander J, Thomas K, Donroe J. Response to substance use during hospitalization: A survey study of current and ideal policies and practices. *Journal Of Hospital Medicine* 2023, 18: 829-834. [PMID: 37475186](#), [DOI: 10.1002/jhm.13162](#).
  52. Entrup P, Brodsky L, Trimble C, Garcia S, Mohamed N, Deaner M, Martell J, Teater J, Jordan A, **Tetrault J**, Hall O. Years of life lost due to deaths of despair and COVID-19 in the United States in 2020: patterns of excess mortality by gender, race and ethnicity. *International Journal For Equity In Health* 2023, 22: 161. [PMID: 37612748](#), [PMCID: PMC10464324](#), [DOI: 10.1186/s12939-023-01949-9](#).
  53. Kazemitabar M, Nyhan K, Makableh N, Minahan-Rowley R, Ali M, Wazaify M, **Tetrault J**, Khoshnood K. Epidemiology of substance use and mental health disorders among forced migrants displaced from the MENAT region: A systematic review and meta-analysis protocol. *PLOS ONE* 2023, 18: e0292535. [PMID: 37797050](#), [PMCID: PMC10553213](#), [DOI: 10.1371/journal.pone.0292535](#).

#### Peer-Reviewed Case Reports and Technical Notes

1. Kapo J, Blatt L, **Tetrault J**, Weimer M. Addiction Medicine Specialists in Your Back Pocket: Building an Essential Collaboration (FR434). *Journal Of Pain And Symptom Management* 2020, 59: 463-464. [DOI: 10.1016/j.jpainsymman.2019.12.143](#).

#### Books

1. Tetrault JM, Crothers K. Clinical update: What are the pulmonary effects of smoking marijuana? *The Journal of Respiratory Diseases*. 2007, 28(6):253-254



2. Tetrault JM, O'Connor PG. Opioid Intoxication and Withdrawal. In Principles of Addiction Medicine, Fourth Edition. Lippincott, Williams Wilkins, Inc. Philadelphia, PA 2009, Pp 589-603.
3. Tetrault JM, Fiellin DA, Sullivan LE. Substance Use and HIV: Treatment Challenges. The AIDS Reader 2019, Vol. No. August 3, 2010
4. Tetrault JM, Sullivan LE, Fiellin DA, Medical Management in Handbook of Office Based Buprenorphine for Opioid Dependence. 2011. Renner JA, Levounis P, eds. American Psychiatric Publishing. Pp 239-267.
5. Tetrault JM, Sullivan LE, Fiellin DA. Medical Management in Handbook of Office Based Buprenorphine for Opioid Dependence. 2011. Renner JA, Levounis P, eds. American Psychiatric Publishing. Pp 239-267.
6. Handbook of Office Based Buprenorphine for Opioid Dependence. 2011. Renner JA, Levounis P, eds. American Psychiatric Publishing. Pp 239-267.
7. Tetrault JM, O'Connor. Opioid Intoxication and Withdrawal. In Principles of Addiction Medicine, Fifth Edition. Wolters Kluwer. Philadelphia, PA. 2014. Pp 668-685.
8. Tetrault JM, O'Connor PG. Unhealthy alcohol use, including alcohol use disorder: Epidemiology, pathogenesis, clinical manifestations, course assessment, and diagnosis. UpToDate Topic. December, 2014. Updated Sept 13, 2018.
9. International AIDS Society Cases on the Web Activity. October 21, 2015, Updated November 1, 2016
10. Holt SR, Tetrault JM. Ambulatory management of alcohol withdrawal syndrome. UpToDate topic. 2016. Updated Nov 30, 2017
11. Tetrault JM, O'Connor PG. Opioid Intoxication and Withdrawal. In Principles of Addiction Medicine, Sixth Edition. Wolters Kluwer. Philadelphia, PA. 2018. Pp 741-756.
12. Tetrault JM and Edelman EJ. Considerations in the treatment of opioid use disorder in patients with HIV infection and HIV/HCV coinfection. International Antiviral Society (IAS)-USA. May, 21, 2019. <https://www.iasusa.org/courses/cow94/>
13. Morford K and Tetrault JM. Opioid Intoxication and Withdrawal. In Principles of Addiction Medicine: The Essentials, Third Edition. Lippincott, Williams Wilkins, Inc. Philadelphia, PA. 2019.
14. Morford, KL, Falker CG, Tetrault, JM. in Treating Opioid Use Disorder in General Medical Settings. Editor, Wakeman, SE.
15. Robinson, D and Tetrault JM. Treatment of Opioid Use Disorder in Pocket Medicine. Editor: Wakeman, SE

#### Commentaries, Editorials and Letters

1. **Tetrault JM**, Fiellin DA. More Beds or More Chairs? Using a Science-Based Approach to Address the Opioid Epidemic. Annals Of Internal Medicine 2017, 168: 73-74. [PMID: 29159399](#), [DOI: 10.7326/m17-2854](#).
2. Weimer MB, Tetrault JM, Allen JC. We must invest in addiction treatment providers. New Haven Register. Op-Ed. March 25, 2019
3. Morford, KM, Tetrault JM. Building the addiction medicine workforce to address the opioid epidemic: Critical steps for medical education. Connecticut Medicine. 2019. 83 (5): 211-216.
4. Weimer MB, **Tetrault JM**, Fiellin DA. Patients With Opioid Use Disorder Deserve Trained Providers. Annals Of Internal Medicine 2019, 171: 931-932. [PMID: 31766053](#), [DOI: 10.7326/m19-2303](#).



5. Weimer MB, **Tetrault JM**, Fiellin DA. Patients With Opioid Use Disorder Deserve Trained Providers. *Annals Of Internal Medicine* 2020, 172: 774-775. [PMID: 32479150](#), [DOI: 10.7326/I20-0084](#).
6. Chan CA, **Tetrault JM**, Fiellin DA, Weimer MB. SOAPs and SUDs: Patients With Substance Use Disorders and What Clinicians Should Know About the Cures Act. *Journal Of Addiction Medicine* 2021, 16: 141-142. [PMID: 34049315](#), [DOI: 10.1097/adm.0000000000000879](#).
7. Biegacki ET, **Tetrault JM**, Fiellin DA. Commentary Article: Strategic Planning for Addiction Programs within Academic Medical Centers: Examples from the Yale Program in Addiction Medicine. *Substance Abuse* 2022, 43: 1215-1220. [PMID: 35657646](#), [DOI: 10.1080/08897077.2022.2074606](#).